Behavioral effects of orally administered glycine in socially housed monkeys chronically treated with phencyclidine

Psychopharmacology

Volumn 192, Issue 1, 2007, Pages 27-38

  Linn, Gary S ^a   O'Keeffe, Robert T ^a   Lifshitz, Kenneth ^a   Schroeder, Charles ^a   Javitt, Daniel C ^a  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Glycine; NMDA receptor; Nonhuman primate model; Phencyclidine (PCP); Psychotomimetic; Schizophrenia

Indexed keywords

GLYCINE; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DISEASE MODEL; DRUG BLOOD LEVEL; FEMALE; MONKEY; NEGATIVE SYNDROME; NONHUMAN; OSMOTIC MINIPUMP; PHYSIOLOGICAL STRESS; POSITIVE SYNDROME; PRIMATE; PRIORITY JOURNAL; SCHIZOPHRENIA; STEREOTYPY; TREATMENT DURATION; TREATMENT OUTCOME;

ANIMALS; BEHAVIOR, ANIMAL; CEBUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLYCINE; GLYCINE AGENTS; HALLUCINOGENS; MALE; MOTOR ACTIVITY; PHENCYCLIDINE; SCHIZOPHRENIA; STEREOTYPED BEHAVIOR; STRESS, PSYCHOLOGICAL;

EID: 34247568367     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-0771-6     Document Type: Article

References (87)

1. Altmann J (1974) Observational study of social behavior: sampling methods. Behaviour 49:227-265
2. Balster RL, Chait LD (1978) The behavioral effects of phencyclidine in animals. In: Peterson RC, Stillman RC (eds) Phencyclidine (PCP) abuse: an appraisal. NIDA Res Monogr 21:53-65
3. Burns R, Lerner S (1981) The effects of phencyclidine in man: a review. In: Domino E (ed) PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp 449-469
4. Castner SA, Goldman-Rakic PS (1999) Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in rhesus monkeys. Neuropsychopharmacology 20:10-28
5. Chen GM, Weston JK (1960) The analgesic and anesthetic effect of 1-(1-phenylcyclohexyl) piperidine HCI on the monkey. Anesth Analg 39:132-137
6. Cheney DL, Seyfarth RM (1989) Redirected aggression and reconciliation among vervet monkeys, Cercopithecus aethiops. Behaviour 110:258-275
7. Cochran SM, Steward LJ, Kennedy MB, McKerchar CE, Pratt JA, Morris BJ (2003) Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28:265-275
8. Coyle JT (1996) The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 3:241-253
9. Coyle JT, Tsai G (2004) The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology 174:32-38
10. Curran HV, Monaghan L (2001) In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction 96:749-760
11. DeAngelis GG, Goldstein E (1978) Long term treatment of adolescent PCP abusers. In: Peterson RC, Stillman RI (eds) Phencyclidine (PCP) abuse: an appraisal, NIDA Res Monogr 21, US Government Printing Office, Washington, DC, pp 254-271
12. Diaz P, Bhaskara S, Dursun SM, Deakin B (2005) Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results. J Clin Psychopharmacol 25:277-278
13. Dingledine R, Kleckner NW, McBain CJ (1990) The glycine coagonist site of the NMDA receptor. Adv Exp Med Biol 268:17-26
14. Ellinwood EH Jr (1971) Effect of chronic methamphetamine intoxication in rhesus monkeys. Biol Psychiatry 3:25-32
15. Ellison G (1995) The N-methyl-D-aspartate anatagonists phencyclidine, ketamine and dizolcipine as both behavioral and anatomical models of the dementias. Brain Res Brain Res Rev 20:250-267
16. Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC (2000) Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 57:826-828
17. Fishkin RJ, Zhou L, Winslow JT (1996) PCP-induced deficits in squirrel monkey social behavior are differentially affected by clozapine and haloperidol. Soc Neurosci Abstracts 22:177
18. Fleiss JC (1981) Statistical methods for rates and proportions, 2nd edn. Wiley, New York
19. Goff DC, Henderson DC, Evins AE, Amico E (1999a) A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 45:512-514
20. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT (1999b) A placebo-controlled trial of D- cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56:21-27
21. Goldstein JM (2000) The new generation of antipsychotic drugs: How atypical are they? Int J Neuropsychopharmacol 3:339-349
22. Goosen C (1981) Abnormal behavior patterns in rhesus monkeys: symptoms of mental disease? Biol Psychiatry 16:697-716
23. Heresco-Levy U, Javitt DC (2004) Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res 66:89-96
24. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D (1996) Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169:610-617
25. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M (1999) Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56:29-36
26. Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC (2002) Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry 159:480-482
27. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC (2004) High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 55:165-171
28. Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, Catinari S, Ermilov M (2005) D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 57:577-585
29. Hood WF, Compton RP, Monahan JB (1989) D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett 98:91-95
30. Javitt DC (2004) Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9:984-997, 979
31. Javitt DC, Zukin SR (1989) Interaction of [3H]MK-801 with multiple states of the N-methyl- D-aspartate receptor complex of rat brain. Proc Natl Acad Sci USA 86:740-744
32. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308
33. Javitt DC, Sershen H, Hashim A, Lajtha A (1997) Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology 17:202-204
34. Javitt DC, Balla A, Sershen H, Lajtha A (1999) Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol Psychiatry 45:668-679
35. Javitt DC, Silipo G, Cienfuegos A, Shelley AM, Bark N, Park M, Lindenmayer JP, Suckow R, Zukin SR (2001) Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol 4:385-391
36. Javitt DC, Balla A, Burch S, Suckow R, Xie S, Sershen H (2004) Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D- aspartate receptor/glycine-site agonists. Neuropsychopharmacology 29:300-307
37. Javitt DC, Duncan L, Balla A, Sershen H (2005) Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry 10:275-287
38. Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225
39. Jentsch JD, Redmond DE, Elsworth JD, Taylor JR, Youngren KD, Roth RH (1997) Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 277:953-955
40. Jentsch JD, Roth RH, Taylor JD, Roth RH (2000) Object retrieval/detour deficits in monkeys produced by prior subchronic phencyclidine administration: evidence for cognitive impulsivity. Biol Psychiatry 48:415-424
41. Kirkpatrick B, Carpenter WT (1995) Drug development and the deficit syndrome of schizophrenia. Biol Psychiatry 38:277-278
42. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatry 51:199-214
43. Lahti AC, Koffel B, Laporte D, Tamminga CA (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9-19
44. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223
45. Lifshitz K, O'Keeffe RT, Lee KL, Avery J (1985) KIBOS: a microcomputerized system for the continuous collection and analysis of behavioral data. Appl Anim Behav Sci 13:203-218
46. Lifshitz K, O'Keeffe RT, Lee KL (1987) Cebus monkey behavioral interactions with fluphenazine decanoate, d-amphetamine and environmental stress. Psychopharmacol Bull 23:487-492
47. Lifshitz K, O'Keeffe RT, Lee KL, Linn GS, Mase D, Avery J, Lo ES, Cooper TB (1991) Effect of extended depot fluphenazine treatment and withdrawal on social and other behaviors of Cebus apella monkeys. Psychopharmacology 105:492-500
48. Lifshitz K, O'Keeffe RT, Linn GS, Lee KL, Camp-Bruno JA, Suckow RF (1997) Effects of dopamine agonists on Cebus apella monkeys with previous long-term exposure to fluphenazine. Biol Psychiatry 41:657-667
49. Linn GS, Javitt DC (2001) Phencyclidine (PCP) induced deficits of prepulse inhibition in monkeys. Neuroreport 12:117-120
50. Linn GS, Mase D, LaFrancois D, O'Keeffe RT, Lifshitz K (1995) Social and menstrual cycle phase influences on the behavior of group-housed Cebus apella. Am J Primatol 35:41-57
51. Linn GS, O'Keeffe RT, Schroeder CE, Lifshitz K, Javitt DC (1999) Behavioral effects of chronic phencyclidine in socially housed monkeys. Neuroreport 10:2789-2793
52. Linn GS, O'Keeffe RT, Lifshitz K, Lee K, Camp-Lifshitz J (2001) Increased incidence of dyskinesias and other behavioral effects of re-exposure to neuroleptic treatment in social colonies of Cebus apella monkeys. Psychopharmacology 153:285-294
53. Linn GS, Negi SS, Gerum SV, Javitt DC (2003) Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys. Psychopharmacology 169:234-239
54. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959) Study of new schizophrenomimetic drug-Sernyl. AMA Arch Neurol Psychiatry 81:363-369
55. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A (1996) NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14:301-308
56. Mason GJ (1991) Stereotypies: a critical review. Anim Behav 41:1015-1037
57. Mason GJ (1993) Forms of stereotypic behavior. In: Lawrence AB, Rushen J (eds) Stereotypic animal behavior. Cab International, Wallingford, pp 8-40
58. Meltzer HY (1997) Treatment-resistant schizophrenia-the role of clozapine. Curr Med Res Opin 14:1-20
59. Millan MJ (2005) N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology 179:30-53
60. Miller RE, Levine JM, Mirsky TA (1973) Effects of psychoactive drugs on non-verbal communication and group social behavior of monkeys. J Pers Soc Psychol 28:396-405
61. Morris R, Anderson E, Lynch G, Baudry M (1986) Selective impairment of learning and blockage of long-term potentiation by an N-methyl- D-aspartate receptor antagonist AP5. Nature 319:774-776
62. O'Keeffe RT, Lifshitz K, Linn G (1983) Relationships among dominance, interanimal spatial proximity and affiliative social behavior in stumptail macaques (Macaca arctoides). Appl Anim Ethol 9:331-339
63. Olney JW, Newcomer JW, Farber NB (1999) NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33:523-533
64. Randrup A, Munvad I (1974) Pharmacology and physiology of stereotyped behavior. J Psychiatr Res 11:1-10
65. Reynolds IJ, Miller RJ (1990) Allosteric modulation of N-methyl-D-aspartate receptors. Adv Pharmacol 21:101-126
66. Ridley RM, Baker HF (1982) Stereotypy in monkeys and humans. Psychol Med 12:61-72
67. Ridley RM, Baker HF (1983) Is there a relationship between social isolation, cognitive inflexibility, and behavioral stereotypy? An analysis of the effects of amphetamine in the marmoset. Prog Clin Biol Res 131:101-135
68. Rujescu D, Bender A, Keck M, Hartmann AM, Ohl F, Raeder H, Giegling I, Genius J, McCarley RW, Moller HJ, Grunze H (2006) A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol Psychiatry 59:721-729
69. Sams-Dodd F, Newman JD (1997) Effects of administration regime on the psychotomimetic properties of d-amphetamine on the squirrel monkey (Saimiri sciureus). Pharmacol Biochem Behav 57:571-580
70. Sayed Y, Garrison JM (1983) The dopamine hypothesis of schizophrenia and the antagonistic action of neuroleptic drugs-a review. Psychopharmacol Bull 19:283-288
71. Schiørring E (1979a) Social isolation and other behavioral changes in groups of adult vervet monkeys (Cercopithecus aethiops) produced by low nonchronic doses of d-amphetamine. Psychopharmacology 64:297-302
72. Schiørring E (1979b) An open field study of stereotyped locomotor activity in amphetamine-treated rats. Psychopharmacology 66:281-287
73. Schlemmer RF, Davis JM (1983) A comparison of three psychotomimetic- induced models of psychosis in nonhuman primate social colonies. In: Miczek K (ed) Ethopharmacology: primate models of neuropsychiatric disorders. Alan R. Liss, New York, pp 33-78
74. Seigel RK (1978) Phencyclidine and ketamine intoxication: a study of four populations of recreational users. In: Peterson RC, Stillman RI (eds) Phencyclidine (PCP) Abuse: an appraisal. NIDA Research Monograph 21, US Government Printing Office, Washington, DC, pp 254-271
75. Singer M, Mirhej G, Shaw S, Saleheen H, Vivian J, Hastings E, Rohena L, Jennings D, Navarro J, Santelices C, Wu AH, Smith A, Perez A (2005) When the drug of choice is a drug of confusion: embalming fluid use in inner city Hartford, CT. J Ethn Subst Abuse 4:73-96
76. Snyder SH (1981) Dopamine receptors, neuroleptics, and schizophrenia. Am J Psychiatry 138:460-464
77. Steinpreis RE (1996) The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis. Behav Brain Res 74:45-55
78. Stringer J, Greenfield L, Hackett J, Guyenet P (1983) Blockage of long-term potentiation by phencyclidine and sigma opiates in the hippocampus in vivo and in vitro. Brain Res 280:127-138
79. Tamminga CA (1998) Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 12:21-36
80. Thompson DM, Winsauer PJ, Mastropaolo J (1987) Effects of phencyclidine, ketamine and MDMA on complex operant behavior in monkeys. Pharmacol Biochem Behav 26:401-405
81. Toth E, Lajtha A (1986) Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem Res 11:393-400
82. Tsai G, Yang P, Chung LC, Lange N, Coyle JT (1998) D-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44:1081-1089
83. Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT (1999) D-Serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 156:1822-1825
84. Tsai GE, Yang P, Chang Y-C, Chong M-Y (2006) D-Alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 59:230-234
85. Tuominen HJ, Tiihonen J, Wahlbeck K (2005) Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 72:225-234
86. Walberg CB, McCarron MM, Schulze BN (1983) Quantitation of phencyclidine in serum by enzyme immunoassay: results in 405 patients. J Anal Toxicol 7:106-110
87. Woods SW, Thomas L, Tully E, Hawkins KA, Miller TJ, Rosen JL, Pearlson G, McGlashan TH (2004) Effects of oral glycine in the schizophrenia prodrome. Schizophr Res 70:79